Fulcrum Therapeutics (FULC) Interest Expenses (2018 - 2026)
Fulcrum Therapeutics (FULC) posted quarterly Interest Expenses of $5.6 million for Q2 2026, down 74.65% year-over-year from $22.2 million in Q2 2025, and down 79.26% quarter-over-quarter from $27.1 million in Q1 2026.
Fulcrum Therapeutics (FULC) Interest Expenses (2018 - 2026) Analysis & Trends
Fulcrum Therapeutics (FULC) has reported Interest Expenses for 9 consecutive years, with $5.6 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Interest Expenses fell 74.65% year-over-year to $5.6 million; the TTM figure through Jun 2026 stood at $5.6 million (down 74.65% YoY), while the FY2025 annual figure was $76.5 million, up 47.83% from the prior year.
- Interest Expenses retreated to $5.6 million in Q2 2026 per FULC's latest filing, from $27.1 million in the prior quarter.
- Across five years, Interest Expenses topped out at $67.3 million in Q1 2022 and bottomed at $1.9 million in Q4 2022.
- Historically, Interest Expenses has averaged $21.5 million across 5 years, with a median of $14.6 million in 2023.
- Annual changes were most pronounced in 2022 — Interest Expenses slumped 98.01% — and 2025, when it jumped 1046.77%.
- Fulcrum Therapeutics' Interest Expenses stood at $1.9 million in 2022, then surged by 701.74% to $15.1 million in 2023, then plunged by 64.58% to $5.4 million in 2024, then surged by 1046.77% to $61.4 million in 2025, then slumped by 90.85% to $5.6 million in 2026.
- Business Quant data shows FULC's Interest Expenses at $5.6 million in Q2 2026, $27.1 million in Q1 2026, and $61.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Fulcrum Therapeutics | 285.31 Mn | 285.31 Mn | - | 5.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.62 Mn |
| Jun 30, 2026 | 5.62 Mn |
| Mar 31, 2026 | 27.09 Mn |
| Mar 31, 2026 | 27.09 Mn |
| Dec 31, 2025 | 61.39 Mn |
| Dec 31, 2025 | 61.39 Mn |
| Sep 30, 2025 | 43.30 Mn |
| Sep 30, 2025 | 43.30 Mn |
| Jun 30, 2025 | 22.17 Mn |
| Jun 30, 2025 | 22.17 Mn |
| Mar 31, 2025 | 8.96 Mn |
| Mar 31, 2025 | 8.96 Mn |
| Dec 31, 2024 | 5.35 Mn |
| Dec 31, 2024 | 5.35 Mn |
| Sep 30, 2024 | 1.30 Mn |
| Sep 30, 2024 | 1.30 Mn |
| Jun 30, 2024 | 12.34 Mn |
| Jun 30, 2024 | 12.34 Mn |
| Mar 31, 2024 | 35.11 Mn |
| Mar 31, 2024 | 35.11 Mn |